CONCLUSION

The evolution of cancer genomics, rooted in historical discoveries, has led to significant advancements in understanding and treating cancer. Genomic technologies, liquid biopsy, immunogenomics, ML, and targeted therapies have reshaped cancer research and care. Challenges such as intratumor heterogeneity persist, but promising developments, including combination therapies, are emerging. Ethical considerations in genetic information use and the societal impact of genomics require ongoing attention. As we navigate this dynamic landscape, interdisciplinary collaboration and ethical reflection will be crucial for realizing the full potential of genomic healthcare in cancer.